Published in J Biol Chem on October 28, 1994
A phosphotyrosine displacement mechanism for activation of Src by PTPalpha. EMBO J (2000) 1.90
Two mechanisms activate PTPalpha during mitosis. EMBO J (2001) 1.10
Src family kinases and paclitaxel sensitivity. Cancer Biol Ther (2011) 1.05
Mitotic activation of protein-tyrosine phosphatase alpha and regulation of its Src-mediated transforming activity by its sites of protein kinase C phosphorylation. J Biol Chem (2002) 0.98
Phosphorylation of unique domains of Src family kinases. Front Genet (2014) 0.82
SRC family kinases and receptors: analysis of three activation mechanisms by dynamic systems modeling. Biophys J (2007) 0.80
Expression and purification of Src-family kinases for solution NMR studies. Methods Mol Biol (2012) 0.78
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
Retracted Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A (1995) 1.93
Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem (1995) 1.81
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis (1997) 1.34
The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem (1999) 1.22
Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus. J Cell Biochem (1992) 1.06
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J Biol Chem (1990) 1.05
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res (1998) 1.02
Retracted 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci U S A (1994) 1.01
Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm (Weinheim) (1996) 0.90
Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J Biol Chem (1996) 0.89
Immunochemical mapping of alpha-2 interferon. Biochemistry (1985) 0.87
Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors. Eur J Biochem (1992) 0.83
Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase. Biochem J (1992) 0.82
Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors. Structure (1997) 0.81
Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src. Oncogene (1999) 0.81
Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity. Anal Biochem (1992) 0.81
Activation of adenylate cyclase in bovine corpus-luteum membranes by human choriogonadotropin, guanine nucleotides and NaF. Biochem J (1981) 0.78
Hormonal activation of bovine luteal adenylate cyclase [proceedings]. Biochem Soc Trans (1979) 0.77
Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res (1992) 0.77
Paeciloquinones A, B, C, D, E and F: new potent inhibitors of protein tyrosine kinases produced by Paecilomyces carneus. I. Taxonomy, fermentation, isolation and biological activity. J Antibiot (Tokyo) (1995) 0.77
Inhibition of epidermal growth factor-mediated ERK1/2 activation by in situ electroporation of nonpermeant [(alkylamino)methyl]acrylophenone derivatives. DNA Cell Biol (1998) 0.76
Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis. Curr Opin Drug Discov Devel (1999) 0.75
Cellular and in vivo characterization of the MCR rat mammary tumor model. Int J Cancer (1993) 0.75
Retractions. Proc Natl Acad Sci U S A (1998) 0.75
The effect of dimethyl 3,3'-dithiobispropionimidate on the adenylate cyclase activity of bovine corpus luteum; stimulation of particulate enzyme activity and the stabilization of activity to dispersion in detergent [proceedings]. Biochem Soc Trans (1980) 0.75
Hepatitis B virus polymerase gene: expression of the long open reading frame using the baculovirus expression system. J Gen Virol (1992) 0.75
Activation of bovine luteal adenylate cyclase by human choriogonadotropin in vitro: persistence of the activated state following preactivation and washing [proceedings]. Biochem Soc Trans (1980) 0.75
A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors. Int J Cancer (1996) 0.75